Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has reported that its Atriance drug for rare and difficult to treat leukemias and lymphomas has been recommended for approved by the European Medicines Agency.
Subscribe to our email newsletter
The drug is designed to treat T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) patients whose disease has not responded to, or has relapsed following, treatment with at least two chemotherapy regimens.
Atriance will now be considered for final marketing approval by the European Commission, which normally takes place within 90 days.